Abstract

BACKGROUND: Therapeutic drug monitoring (TDM) has been advocated to promote the efficacy of antituberculosis agents. Cycloserine (CS) is a second-line anti-tuberculosis drug whose serum concentrations in tuberculosis (TB) patients are largely unknown. OBJECTIVES: To investigate serum CS concentrations after drug ingestion in TB patients. METHODS: Multidrug-resistant TB patients who were taking CS in a tertiary care centre in northern Taiwan between 1 April 2009 and 31 October 2009 were enrolled in the study. Serum CS concentrations were measured at 2 and 6 h after drug administration. RESULTS: Of 32 patients enrolled, 23 were males and 9 females. The mean CS dose was 8.8 ± 1.3 mg/kg. The mean serum concentrations at 2 and 6 h were respectively 19.7 ± 8.3 and 18.1 ± 8.7 μg/ml. Seven patients (22%) had serum drug concentrations that were higher at 6 h than at 2 h, 12 (38%) had peak serum concentrations within the recommended range of 20-35 μg/ml; 18 patients (56%) had concentrations 35 μg/ml. CONCLUSION: Lower than recommended serum CS concentrations and delayed absorption were common. It is essential to develop practical TDM to maintain proper serum drug concentrations.

Original languageEnglish
JournalInternational Journal of Tuberculosis and Lung Disease
Volume18
Issue number5
DOIs
Publication statusPublished - May 1 2014

Fingerprint

Cycloserine
Multidrug-Resistant Tuberculosis
Taiwan
Serum
Tuberculosis
Pharmaceutical Preparations
Drug Monitoring
Tertiary Care Centers
Eating

Keywords

  • Cycloserine
  • MDR-TB
  • Therapeutic drug monitoring
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases
  • Medicine(all)

Cite this

@article{f2bb9ec48271493aa7a7dce557142771,
title = "Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan",
abstract = "BACKGROUND: Therapeutic drug monitoring (TDM) has been advocated to promote the efficacy of antituberculosis agents. Cycloserine (CS) is a second-line anti-tuberculosis drug whose serum concentrations in tuberculosis (TB) patients are largely unknown. OBJECTIVES: To investigate serum CS concentrations after drug ingestion in TB patients. METHODS: Multidrug-resistant TB patients who were taking CS in a tertiary care centre in northern Taiwan between 1 April 2009 and 31 October 2009 were enrolled in the study. Serum CS concentrations were measured at 2 and 6 h after drug administration. RESULTS: Of 32 patients enrolled, 23 were males and 9 females. The mean CS dose was 8.8 ± 1.3 mg/kg. The mean serum concentrations at 2 and 6 h were respectively 19.7 ± 8.3 and 18.1 ± 8.7 μg/ml. Seven patients (22{\%}) had serum drug concentrations that were higher at 6 h than at 2 h, 12 (38{\%}) had peak serum concentrations within the recommended range of 20-35 μg/ml; 18 patients (56{\%}) had concentrations 35 μg/ml. CONCLUSION: Lower than recommended serum CS concentrations and delayed absorption were common. It is essential to develop practical TDM to maintain proper serum drug concentrations.",
keywords = "Cycloserine, MDR-TB, Therapeutic drug monitoring, Tuberculosis",
author = "Hung, {W. Y.} and Yu, {M. C.} and Chiang, {Y. C.} and Chang, {J. H.} and Chiang, {C. Y.} and Chang, {C. C.} and Chuang, {H. C.} and Bai, {Kuan Jen}",
year = "2014",
month = "5",
day = "1",
doi = "10.5588/ijtld.13.0268",
language = "English",
volume = "18",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "5",

}

TY - JOUR

T1 - Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan

AU - Hung, W. Y.

AU - Yu, M. C.

AU - Chiang, Y. C.

AU - Chang, J. H.

AU - Chiang, C. Y.

AU - Chang, C. C.

AU - Chuang, H. C.

AU - Bai, Kuan Jen

PY - 2014/5/1

Y1 - 2014/5/1

N2 - BACKGROUND: Therapeutic drug monitoring (TDM) has been advocated to promote the efficacy of antituberculosis agents. Cycloserine (CS) is a second-line anti-tuberculosis drug whose serum concentrations in tuberculosis (TB) patients are largely unknown. OBJECTIVES: To investigate serum CS concentrations after drug ingestion in TB patients. METHODS: Multidrug-resistant TB patients who were taking CS in a tertiary care centre in northern Taiwan between 1 April 2009 and 31 October 2009 were enrolled in the study. Serum CS concentrations were measured at 2 and 6 h after drug administration. RESULTS: Of 32 patients enrolled, 23 were males and 9 females. The mean CS dose was 8.8 ± 1.3 mg/kg. The mean serum concentrations at 2 and 6 h were respectively 19.7 ± 8.3 and 18.1 ± 8.7 μg/ml. Seven patients (22%) had serum drug concentrations that were higher at 6 h than at 2 h, 12 (38%) had peak serum concentrations within the recommended range of 20-35 μg/ml; 18 patients (56%) had concentrations 35 μg/ml. CONCLUSION: Lower than recommended serum CS concentrations and delayed absorption were common. It is essential to develop practical TDM to maintain proper serum drug concentrations.

AB - BACKGROUND: Therapeutic drug monitoring (TDM) has been advocated to promote the efficacy of antituberculosis agents. Cycloserine (CS) is a second-line anti-tuberculosis drug whose serum concentrations in tuberculosis (TB) patients are largely unknown. OBJECTIVES: To investigate serum CS concentrations after drug ingestion in TB patients. METHODS: Multidrug-resistant TB patients who were taking CS in a tertiary care centre in northern Taiwan between 1 April 2009 and 31 October 2009 were enrolled in the study. Serum CS concentrations were measured at 2 and 6 h after drug administration. RESULTS: Of 32 patients enrolled, 23 were males and 9 females. The mean CS dose was 8.8 ± 1.3 mg/kg. The mean serum concentrations at 2 and 6 h were respectively 19.7 ± 8.3 and 18.1 ± 8.7 μg/ml. Seven patients (22%) had serum drug concentrations that were higher at 6 h than at 2 h, 12 (38%) had peak serum concentrations within the recommended range of 20-35 μg/ml; 18 patients (56%) had concentrations 35 μg/ml. CONCLUSION: Lower than recommended serum CS concentrations and delayed absorption were common. It is essential to develop practical TDM to maintain proper serum drug concentrations.

KW - Cycloserine

KW - MDR-TB

KW - Therapeutic drug monitoring

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84899575373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899575373&partnerID=8YFLogxK

U2 - 10.5588/ijtld.13.0268

DO - 10.5588/ijtld.13.0268

M3 - Article

C2 - 24903799

AN - SCOPUS:84899575373

VL - 18

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 5

ER -